Top Back to top

Infections following CAR-T therapy. A retrospective collaborative study between the Infectious Diseases Working Party (IDWP), the Cellular Therapy and Immunobiology Working Party (CTIWP), the Transplant Complications Working Party (TCWP) of the EBMT, the European Hematology Association (EHA), and the Medical College of Wisconsin.

GoCART Coalition
Infectious Diseases Working Party (IDWP)
Cellular Therapy & Immunobiology Working Party (CTIWP)
Transplant Complications Working Party (TCWP)
Study type:
Study number:
Type of Stem Cell Treatment:
Non-Hodgkin’s Lymphoma (NHL)
Acute Lymphatic Leukaemia (ALL)
Short title:
Primary objective:
The survey aims to gather information on the management of surveillance, prophylaxis, and treatment of infections following CAR-T therapy. It will help plan the following steps of the study. For example, the rate of CMV infections is very much dependant on the surveillance and prophylaxis practices, and the analysis of CMV infections rate and severity will be based on the responses on surveillance and prophylaxis from this survey.
Key inclusion criteria:
All EBMT member countries
Principal investigator:
Dina Averbuch
EBMT Study coordinator:
Study coordinator email:
Reason for processing personal data:
Not applicable to surveys
Categories of personal data collected:
Not applicable to surveys
Recipients who may access the data:
Not applicable to surveys
3rd-party processors of Personal Data on behalf of EBMT/Service provider:

Privacy notices

Article 6 lawful basis for processing personal data:
Article 6.1 (a) - Consent (Collection)
Article 9 basis for processing special category data:
Article 9(2) (a) - Consent (Collection)

Data Protection Impact Assessments

Rights available to individuals:
Data portability
Is a Data Protection Impact Assessment required?:
DPIA performed for EBMT Registry (WP & NIS Studies)
Retention Schedule (if possible):
at least 5 years after the final report or first publication of study results